Elevance Health CEO Boudreaux Buys $2.44M Worth of Shares

Elevance Health CEO Gail Boudreaux purchased 8,500 shares at an average price of $286.94 for a total value of $2.44M. Boudreaux now owns 151,020 shares of Elevance. Despite this purchase, shares of Elevance are down 6% to $283.52 in afternoon trading.

Elevance Health (NYSE: ELV) President and CEO Gail Boudreaux recently purchased 8,500 shares of the company’s stock on July 18, 2025, in a series of transactions totaling $2.44 million. The insider buying comes as the healthcare giant's stock trades near its 52-week low, having declined over 11% in the past week. According to InvestingPro analysis, the stock appears undervalued at its current P/E ratio of 11.7x [1].

Boudreaux acquired a total of 8,500 shares of Elevance Health common stock in three separate purchases. The prices paid ranged from $286.07 to $287.96 per share. Specifically, she purchased 2,334 shares at a weighted average price of $286.07, 5,116 shares at a weighted average price of $287.12, and 1,050 shares at a weighted average price of $287.96 [1].

Following these transactions, Boudreaux directly owns 151,020 shares of Elevance Health. She also indirectly owns 60 shares held in a spouse’s revocable trust. This purchase follows a series of adjustments and evaluations following Elevance's second-quarter earnings report. The company reported earnings per share of $8.84, a 12.6% decline year-over-year and $0.14 below consensus estimates [1].

Despite this insider buying activity, Elevance Health shares experienced an afternoon dip, declining by 6% to $283.52, although they have recovered slightly from earlier lows. Based on the one-year price targets offered by 19 analysts, the average target price for Elevance Health Inc (ELV) is $439.91, with a high estimate of $556.33 and a low estimate of $310.00. The average target implies an upside of 55.94% from the current price of $282.10 [2].

The consensus recommendation from 24 brokerage firms is currently 2.1, indicating an "Outperform" status. The rating scale ranges from 1 to 5, where 1 signifies a Strong Buy, and 5 denotes a Sell. Based on GuruFocus estimates, the estimated GF Value for Elevance Health Inc (ELV) in one year is $634.53, suggesting an upside of 124.93% from the current price of $282.1 [2].

Elevance Health reported a 14% year-over-year increase in operating revenue, reaching $49.4 billion, driven by higher premium yields and recent acquisitions. The company delivered adjusted EPS consistent with expectations, reflecting strength in the Medicare Advantage portfolio and disciplined cost management. CarelonRx and Carelon services showed strong performance, with CarelonRx growing operating revenue by over 20% and Carelon services delivering more than 50% growth in revenue [2].

However, Elevance Health revised its full-year 2025 adjusted EPS guidance to approximately $30, reflecting pressures from elevated medical cost trends in ACA and slower Medicaid rate alignment. The company experienced a sequential decline in medical membership, down approximately 200,000, primarily due to reductions in Medicaid membership and lower effectuation rates in the ACA business [2].

References:
[1] https://www.investing.com/news/insider-trading-news/elevance-health-ceo-boudreaux-buys-24-million-in-stock-93CH-4142393
[2] https://www.gurufocus.com/news/2988348/elevance-health-elv-ceo-increases-stake-with-significant-purchase-elv-stock-news